Haemonetics Co. (NYSE:HAE) Stock Position Increased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lifted its position in Haemonetics Co. (NYSE:HAE) by 16.1% during the first quarter, Holdings Channel reports. The institutional investor owned 267,433 shares of the medical instruments supplier’s stock after buying an additional 37,048 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Haemonetics were worth $29,688,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Wells Fargo & Company MN raised its stake in shares of Haemonetics by 17.4% in the 4th quarter. Wells Fargo & Company MN now owns 1,216,040 shares of the medical instruments supplier’s stock worth $144,404,000 after buying an additional 180,109 shares in the last quarter. Royce & Associates LP grew its holdings in shares of Haemonetics by 2.6% in the 4th quarter. Royce & Associates LP now owns 598,756 shares of the medical instruments supplier’s stock worth $71,102,000 after acquiring an additional 15,148 shares during the last quarter. Norges Bank acquired a new position in shares of Haemonetics in the 4th quarter worth $59,775,000. Dimensional Fund Advisors LP grew its holdings in shares of Haemonetics by 3.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 484,103 shares of the medical instruments supplier’s stock worth $57,488,000 after acquiring an additional 17,279 shares during the last quarter. Finally, Thornburg Investment Management Inc. grew its holdings in shares of Haemonetics by 33.5% in the 4th quarter. Thornburg Investment Management Inc. now owns 284,147 shares of the medical instruments supplier’s stock worth $33,742,000 after acquiring an additional 71,355 shares during the last quarter. 96.22% of the stock is currently owned by institutional investors.

HAE has been the topic of a number of recent research reports. Morgan Stanley decreased their target price on Haemonetics from $83.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday. Raymond James lifted their target price on Haemonetics from $145.00 to $155.00 and gave the stock an “outperform” rating in a report on Friday, February 12th. Barrington Research decreased their target price on Haemonetics from $91.00 to $71.00 and set an “outperform” rating on the stock in a report on Friday. Zacks Investment Research downgraded Haemonetics from a “buy” rating to a “hold” rating and set a $125.00 price target on the stock. in a report on Thursday, March 11th. Finally, CJS Securities upgraded Haemonetics from a “market perform” rating to an “outperform” rating in a report on Friday. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Haemonetics has an average rating of “Buy” and a consensus target price of $101.29.

HAE opened at $56.00 on Monday. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of 27.05, a PEG ratio of 5.17 and a beta of 0.56. Haemonetics Co. has a 1 year low of $49.26 and a 1 year high of $142.11. The company has a current ratio of 2.25, a quick ratio of 1.34 and a debt-to-equity ratio of 0.44. The stock has a fifty day moving average price of $89.99 and a 200 day moving average price of $111.81.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 13th. The medical instruments supplier reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.67 by ($0.21). The firm had revenue of $225.00 million for the quarter, compared to analyst estimates of $223.92 million. Haemonetics had a net margin of 11.76% and a return on equity of 22.85%. Haemonetics’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.69 EPS. As a group, sell-side analysts forecast that Haemonetics Co. will post 2.45 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Read More: Why are trading ranges significant?

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.